{
    "clinical_study": {
        "@rank": "1656", 
        "acronym": "EVINEC", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive Everolimus orally, 10 mg/day."
        }, 
        "brief_summary": {
            "textblock": "The study is designed as an open-label, prospective, single arm, multicenter study of\n      everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3\n      after failure of first-line platin-based chemotherapy (open-label pilot study).\n\n      The aim of this study is to provide a second line therapy to patients with any type of\n      platinum based first line chemotherapy, to gather data on disease control rate and\n      progression free survival."
        }, 
        "brief_title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Poorly Differentiated Neuroendocrine Carcinoma,", 
            "Neuroendocrine Carcinoma, Grade 3", 
            "Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3", 
            "Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3", 
            "Neuroendocrine Tumor, Grade 3"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Neuroendocrine", 
                "Neuroendocrine Tumors"
            ]
        }, 
        "detailed_description": {
            "textblock": "As more efficient drugs are urgently needed for the treatment of neuroendocrine tumors the\n      investigator evaluated phosphorylated Mammalian target of rapamycin (mTOR) and effectors in\n      a series of NEC G3 at the Charit\u00e9 Center. Everolimus showed antiproliferative effects in\n      bronchial NET.\n\n      In a second approach the data of this study should be the basis to generate another study to\n      further explore everolimus as maintenance therapy in NEC G3/ NET G3."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent\n\n          2. Male or female \u226518 years of age\n\n          3. Patients with poorly differentiated neuroendocrine carcinoma, neuroendocrine\n             carcinoma G3 (NEC - G3 according to WHO 2010) or well or moderately differentiated\n             neuroendocrine carcinoma (NET - G1/ G2) that switched to G3 (confirmed by histology)\n             or neuroendocrine tumor G3 (NET G3) and disease progression as measured by RECIST\n\n          4. Treatment during first-line therapy with platin-based chemotherapy\n\n          5. Measurable disease according to RECIST 1.1\n\n          6. ECOG status 0-2 (Karnofsky Performance status >= 80%)\n\n          7. Women of child-bearing potential must have a negative pregnancy test\n\n          8. Laboratory requirements:\n\n        Hematology\n\n          -  Absolute neutrophil count \u22651.5x109/L\n\n          -  Platelet count \u2265100x109/L\n\n          -  Leukocyte count > 3.0x109/L\n\n          -  Hemoglobin \u2265 9 g/dL or 5.59 mmol/l\n\n        Hepatic Function\n\n          -  Total bilirubin \u2264 1.5 time the upper limit normal (ULN)\n\n          -  Aspartate aminotransferase (AST) \u2264 3x ULN in absence of liver metastases, or \u2264 5x ULN\n             in presence of liver metastases\n\n          -  Alanine aminotransferase (ALT) \u2264 3x ULN in absence of liver metastases, or \u2264 5x ULN\n             in presence of liver metastases\n\n        Renal Function\n\n          -  Creatinine clearance \u226550 mL/min according to Cockcroft-Gault formula\n\n        Metabolic Function\n\n          -  Magnesium \u2265 lower limit of normal\n\n          -  Calcium \u2265 lower limit of normal\n\n          -  Others: PCT if CRP is elevated to exclude infection, negative Urinary screening test\n             (U-stix)\n\n        Exclusion Criteria:\n\n          1. Known or suspected allergy or hypersensitivity reaction to any of the components of\n             study treatment or their excipients.\n\n          2. Previous therapy with mTOR inhibitor\n\n          3. Concurrent radiotherapy involving target lesions used for this study. Concurrent\n             palliative radiation for non-target lesions is allowed if other target lesions are\n             available outside the involved field; previous pre-operative or post-operative\n             radiotherapy is allowed\n\n          4. History of other malignant tumors within the last 5 years, except basal cell\n             carcinoma or curatively excised cervical carcinoma in situ\n\n          5. Known brain metastases unless adequately treated (surgery or radiotherapy) with no\n             evidence of progression and neurologically stable off anticonvulsants and steroids\n\n          6. Clinically significant cardiovascular disease (including myocardial infarction,\n             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac\n             arrhythmia) \u2264 1 year before enrolment\n\n          7. Inadequate pulmonary function according to the Investigator's judgment, history of\n             interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of\n             interstitial lung disease on baseline chest CT scan\n\n          8. Known active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or HIV infection\n\n          9. Serious concomitant disease or medical condition that in the judgment of the\n             investigator renders the patient at high risk from treatment complication\n\n         10. Any systemic disease requiring oral intake of corticosteroids (except for replacement\n             therapy of corticosteroids - hydrocortisone in case of adrenal or pituitary\n             insufficiency)\n\n         11. Hearing loss > NCI-CTC V.4.03 Grade 3\n\n         12. Patient pregnant or breast feeding, or planning to become pregnant within 8 weeks\n             after the end of treatment\n\n         13. Patient (male or female) is not willing to use highly effective methods of\n             contraception (per institutional standard) during treatment and for 8 weeks (male or\n             female) after the end of treatment.\n\n         14. Concurrent treatment with other experimental drugs or participation in another\n             clinical trial with any investigational drug within 28 days prior to treatment start\n\n         15. Concurrent treatment with inhibitors (e.g. itraconazole, ketoconazole) and inducers\n             (e.g. phenytoin, rifampicin) of Cytochrome P450 3A4 (CYP3A4) and/or the multidrug\n             efflux pump P-glycoprotein (PgP).\n\n         16. Known drug abuse/alcohol abuse\n\n         17. Peripheral polyneuropathy > NCI-CTC V 4.03 Grade 2\n\n         18. Active chronic inflammatory bowel disease\n\n         19. Any condition which might interfere with study objectives (e.g. infections) or would\n             limit the patient's ability to complete the study in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113800", 
            "org_study_id": "AIO-NET-0112", 
            "secondary_id": [
                "CRAD001KDE55T", 
                "2012-004550-28"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Single Arm", 
            "description": "Formulation: 10 mg/day Route: oral (tablet)", 
            "intervention_name": "Everolimus (Afinitor\u00ae)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "link": {
            "description": "Working Group for Medical Oncology (AIO) from the German Cancer Society (DKG)", 
            "url": "http://www.aio-portal.de"
        }, 
        "location": {
            "contact": {
                "email": "marianne.pavel@charite.de", 
                "last_name": "Marianne Pavel, Prof. Dr."
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "13353"
                }, 
                "name": "Charit\u00e9-Universit\u00e4tsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum"
            }, 
            "investigator": {
                "last_name": "Marianne Pavel, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study", 
        "overall_contact": {
            "email": "Katrin.Krause@aio-studien-ggmbh.de", 
            "last_name": "Katrin Krause, B.Sc.", 
            "phone": "+49 30 8145 344", 
            "phone_ext": "32"
        }, 
        "overall_official": {
            "affiliation": "Charit\u00e9-Universit\u00e4tsmedizin", 
            "last_name": "Marianne Pavel, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of adverse events (AEs) overall and by severity, and serious adverse events (SAEs). Severity will be assessed using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) for Adverse Events, version 4.03 (CTCAEv4.03).", 
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "approx. 12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113800"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival (PFS) as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse as per local radiology assessment using Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Objective response rate defined as the rate of best overall response (CR+PR), determined by RECIST V 1.1.", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Disease control rate defined as the rate of best overall response and stable disease (CR+PR+SD), determined by RECIST V 1.1.", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Duration of response is defined as the time from onset of the first objective tumor response (CR/PR) to objective tumor progression or death from any cause.", 
                "measure": "Duration of response (DR)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "OS is defined as the time from date of randomization to the date of death from any cause. If a patient is not known to have died at the date of analysis cut-off, the OS will be censored at the last date of contact.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Quality of life (HRQoL) will be evaluated using the EORTC QLQ-C30", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Percentage of patients showing normalization or a decrease of chromogranin A & B", 
                "measure": "chromogranin A & B", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Time to progression (TTP) is the time from date of start of treatment to the date of event defined as the first documented progression due to underlying cancer.", 
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Percentage of patients showing normalization or a decrease of neuron-specific enolase", 
                "measure": "neuron-specific enolase", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Percentage of patients showing normalization or a decrease of progastrin releasing peptide.", 
                "measure": "progastrin releasing peptide", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Quality of life (HRQoL) will be evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }
        ], 
        "source": "AIO-Studien-gGmbH", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Assign Data Management and Biostatistics GmbH", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Novartis", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "AIO-Studien-gGmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}